Director of the Shanghai Municipal Health and Health Development Research Center and medical reform expert Jin Chunlin: Generic drugs "are not only low-priced" will correct the "price competition"

After the National Health Insurance Administration clarified on July 24 that the 11th batch of centralized procurement would no longer simply consider the lowest bid, Jin Chunlin, director of the Shanghai Health and Health Development Research Center and medical reform expert, told the Securities Times reporter that this move will correct the industry's criticism of the "internal" price problem. In the future, winning will not rely solely on price, but on comprehensive evaluation, while ensuring quality, cost reduction as much as possible. This time, generic drugs are "not only low-priced", and the previous policy of encouraging innovative pricing of innovative drugs, both of which have been positively received by the capital market, will jointly promote the prosperous development of the biopharmaceutical industry.